RxDoctor Payments Data

Remie Saab

Cleveland, OHNPI 1144803156

Payments from drug & device makers

$2,626in general payments, 2019–2025

Across 89 payments — averaging $29.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$584
  • Amgen$289
  • CSL Behring$272
  • Sanofi$207
  • Novartis$154
  • Pharming Healthcare, Inc.$141
  • plus $979 from 16 others

What the payments were for

  • Food & beverage$2,53797%
  • Education$893%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Atorvastatin Calcium31$225
Levothyroxine Sodium20$111
Amlodipine Besylate14$101
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide12$45

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →